"Piperidines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A family of hexahydropyridines.
| Descriptor ID |
D010880
|
| MeSH Number(s) |
D03.383.621
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Piperidines".
Below are MeSH descriptors whose meaning is more specific than "Piperidines".
This graph shows the total number of publications written about "Piperidines" by people in this website by year, and whether "Piperidines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1998 | 2 | 0 | 2 |
| 1999 | 3 | 1 | 4 |
| 2000 | 3 | 0 | 3 |
| 2001 | 6 | 1 | 7 |
| 2002 | 1 | 2 | 3 |
| 2003 | 4 | 2 | 6 |
| 2004 | 4 | 0 | 4 |
| 2005 | 3 | 4 | 7 |
| 2006 | 0 | 3 | 3 |
| 2007 | 3 | 0 | 3 |
| 2008 | 4 | 2 | 6 |
| 2009 | 7 | 0 | 7 |
| 2010 | 2 | 3 | 5 |
| 2012 | 4 | 4 | 8 |
| 2013 | 5 | 1 | 6 |
| 2014 | 2 | 4 | 6 |
| 2015 | 4 | 5 | 9 |
| 2016 | 3 | 11 | 14 |
| 2017 | 4 | 4 | 8 |
| 2018 | 1 | 15 | 16 |
| 2019 | 2 | 5 | 7 |
| 2020 | 4 | 4 | 8 |
| 2021 | 6 | 7 | 13 |
| 2022 | 0 | 7 | 7 |
| 2023 | 1 | 3 | 4 |
| 2024 | 2 | 3 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Piperidines" by people in Profiles.
-
Prolonged complete response to adjuvant tepotinib in a patient with newly diagnosed disseminated glioblastoma harboring mesenchymal-epithelial transition fusion. Oncologist. 2025 Jan 17; 30(1).
-
Sustained benefit of zanubrutinib vs ibrutinib in patients with R/R CLL/SLL: final comparative analysis of ALPINE. Blood. 2024 Dec 26; 144(26):2706-2717.
-
Deuterated water labeling in ibrutinib-treated patients with CLL: leukemia cell kinetics correlate with IGHV, ZAP-70, and MRD. Blood. 2024 Dec 19; 144(25):2678-2681.
-
Anti-Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma: A Nonrandomized Clinical Trial. JAMA Oncol. 2024 Dec 01; 10(12):1672-1680.
-
Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia. Nat Rev Clin Oncol. 2024 Dec; 21(12):867-887.
-
Birth outcomes following bictegravir exposure during pregnancy. AIDS. 2025 Mar 15; 39(4):381-386.
-
CASPER: A Phase I trial combining calaspargase pegol-mnkl and cobimetinib in pancreatic cancer. Future Oncol. 2024; 20(37):2915-2925.
-
Transcriptomic and proteomic differences in BTK-WT and BTK-mutated CLL and their changes during therapy with pirtobrutinib. Blood Adv. 2024 09 10; 8(17):4487-4501.
-
Neoadjuvant PARPi or chemotherapy in ovarian cancer informs targeting effector Treg cells for homologous-recombination-deficient tumors. Cell. 2024 Sep 05; 187(18):4905-4925.e24.
-
Inhibition of SRC-3 as a potential therapeutic strategy for aggressive mantle cell lymphoma. PLoS One. 2024; 19(4):e0289902.